275 related articles for article (PubMed ID: 28732067)
1. Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
Hasegawa S; Matsui T; Hane Y; Abe J; Hatahira H; Motooka Y; Sasaoka S; Fukuda A; Naganuma M; Hirade K; Takahashi Y; Kinosada Y; Nakamura M
PLoS One; 2017; 12(7):e0182045. PubMed ID: 28732067
[TBL] [Abstract][Full Text] [Related]
2. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone.
Shoupe D
Obstet Gynecol; 1994 May; 83(5 Pt 1):679-85. PubMed ID: 8164925
[TBL] [Abstract][Full Text] [Related]
4. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
[TBL] [Abstract][Full Text] [Related]
5. Risk of sexual dysfunction with progestin-based contraceptives in women of child-bearing age.
Guo MY; Sodhi M; Khosrow-Khavar F; Etminan M
Eur J Clin Pharmacol; 2021 Jan; 77(1):133-140. PubMed ID: 32803291
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
7. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
8. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
Gaspard U; Lambotte R
Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptives and the risk of gallbladder disease: a comparative safety study.
Etminan M; Delaney JA; Bressler B; Brophy JM
CMAJ; 2011 May; 183(8):899-904. PubMed ID: 21502354
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
Dinger J; Möhner S; Heinemann K
Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
[TBL] [Abstract][Full Text] [Related]
11. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
12. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.
Sidney S; Cheetham TC; Connell FA; Ouellet-Hellstrom R; Graham DJ; Davis D; Sorel M; Quesenberry CP; Cooper WO
Contraception; 2013 Jan; 87(1):93-100. PubMed ID: 23083525
[TBL] [Abstract][Full Text] [Related]
13. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives.
Burnhill MS
Int J Fertil Womens Med; 1999; 44(1):19-30. PubMed ID: 10206196
[TBL] [Abstract][Full Text] [Related]
14. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
15. [Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations].
Milsom I; Odlind V; von Schoultz B; Ostlund I; Persson E
Lakartidningen; 2002 Jan; 99(1-2):10-2, 15. PubMed ID: 11871161
[No Abstract] [Full Text] [Related]
16. The Effect of Oral Contraceptive Hormones on Anterior Cruciate Ligament Strength.
Konopka JA; Hsue L; Chang W; Thio T; Dragoo JL
Am J Sports Med; 2020 Jan; 48(1):85-92. PubMed ID: 31765227
[TBL] [Abstract][Full Text] [Related]
17. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.
Hampton RM; Fisher AC; Pagano S; LaGuardia KD
Fertil Steril; 2009 Aug; 92(2):434-40. PubMed ID: 18930189
[TBL] [Abstract][Full Text] [Related]
18. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
Merz M; Kroll R; Lynen R; Bangerter K
Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Duijkers IJ; Klipping C; Zimmerman Y; Appels N; Jost M; Maillard C; Mawet M; Foidart JM; Coelingh Bennink HJ
Eur J Contracept Reprod Health Care; 2015; 20(6):476-89. PubMed ID: 26394847
[TBL] [Abstract][Full Text] [Related]
20. Endothelial function across an oral contraceptive cycle in women using levonorgestrel and ethinyl estradiol.
Torgrimson BN; Meendering JR; Kaplan PF; Minson CT
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2874-80. PubMed ID: 17277029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
